Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors

Hafid Alazzouzi,1 Veronica Davalos,1 Antti Kokko,2 Enric Domingo,1 Stefan M. Woerner,3 Andrew J. Wilson,1 Lars Konrad,1 Päivi Laiho,1 Eloi Espín,4 Manel Armengol,5 Kohzoh Imai,6 Hiroyuki Yamamoto,7 John M. Mariadason,1 Johannes F. Gebert,7 Lauri A. Aaltonen,2 Simo Schwartz, Jr.,1 and Diego Arango1

1Molecular Oncology and Aging Group, Molecular Biology and Biochemistry Research Center (CIBBIM), Valle Hebron Hospital Research Institute, Barcelona, Spain; 2Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland; 3Institute of Molecular Pathology/Applied Tumor Biology, University of Heidelberg, Heidelberg, Germany; 4Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, New York; and 5First Department of Internal Medicine, Sapporo Medical University, Sapporo, Japan

Abstract

The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/β-catenin. Premalignant lesions of the colon express high levels of EPHB2 but the expression of this kinase is reduced or lost in most colorectal carcinomas. In addition, inactivation of EPHB2 has been shown to accelerate tumorigenesis initiated by APC mutation in the colon and rectum. In this study, we investigated the molecular mechanisms responsible for the inactivation of EPHB2 in colorectal tumors. We show here the presence of mutations in repetitive sequences in exon 17 of EPHB2 in 6 of 29 adenomas with microsatellite instability (MSI), and 101 of 246 MSI carcinomas (21% and 41%, respectively). Moreover, we found EPHB2 promoter hypermethylation in 54 of the 101 colorectal tumors studied (53%). Importantly, EPHB2 expression was restored after treatment of EPHB2-methylated colon cancer cells with the DNA methyltransferase inhibitor 5-aza-2′-deoxycytidine. In conclusion, in this study, we elucidate the molecular mechanisms of inactivation of EPHB2 and show for the first time the high incidence of frameshift mutations in MSI colorectal tumors and aberrant methylation of the regulatory sequences of this important tumor suppressor gene. (Cancer Res 2005; 65(22): 10170-3)

Introduction

The great majority of colorectal tumors display a constitutive up-regulation of TCF/β-catenin transcriptional activity, most commonly caused by mutations in the tumor suppressor gene APC (1). Increased activity of the TCF/β-catenin pathway is therefore a hallmark of colorectal cancer. This complex transcriptionally up-regulates key genes that are important in the development of these tumors. However, potentially oncogenic changes are often counterbalanced by additional effects of these alterations that abrogate a possible growth advantage. For example, deregulation and amplification of the transcription factor c-MYC is one of the most common events in colorectal tumors. Although c-MYC can promote cell growth by regulating the expression levels of multiple cell cycle regulators, it can also induce apoptosis through the modulation of proapoptotic genes such as BAX (2). The receptor tyrosine kinase EPHB2 has recently been shown to be a direct transcriptional target of TCF/β-catenin and premalignant lesions of the colon express high levels of expression of this kinase (3–5). However, EPHB2 expression is reduced in colonic carcinomas and low levels are correlated with tumor progression (5). In addition, inactivation of EPHB2 has been shown to accelerate tumorigenesis initiated by APC mutations in the colon and rectum of APCMin/+ mice (5), demonstrating that EPHB2 is an important tumor suppressor in the large intestine. Therefore, despite being up-regulated by TCF/β-catenin signaling, inactivation of EPHB2 seems to be an important requirement in the progression of colorectal tumors. However, it is currently not known how EPHB2 activity is lost during tumor progression.

Approximately 15% of the tumors of the colon and the rectum display a microsatellite unstable phenotype (MSI). This is observed as frequent insertions and deletions within short repetitive sequences known as microsatellites. Mutations within coding regions of the target genes result in frameshifts that can disrupt protein function. Mutations that confer a growth advantage to the cells are selected and can be found in a significant percentage of colorectal tumors with an MSI phenotype. Genes frequently targeted by these mutation include those involved in molecular mechanisms important in the development of colorectal tumors, including the transforming growth factor-β pathway, Wnt signaling, and DNA damage repair and apoptosis pathways (6). Because loss of EPHB2 activity is an important step in tumor progression, and because this receptor contains an A9 track in exon 17 that could be a target for mutation in MSI tumors, we screened this region for alterations in MSI tumor cell lines as well as in primary adenomas and carcinomas with MSI.

Hypermethylation of cytosines located within CpG islands in the promoter of tumor suppressor genes is emerging as an important mechanism of gene silencing in both microsatellite stable (MSS) and unstable colorectal tumors, and has been reported to disrupt important pathways in colorectal tumorigenesis, including the TP53 pathway (p14ARF), the WNT signaling pathway (APC, E-cadherin), DNA repair (MGMT, hMLH1, BRCA1), apoptosis (DAPK), and metastasis (E-cadherin, TIMP3; ref. 7). We identified a CpG island spanning the proximal EPHB2 promoter and the first exon, and investigated the possible contribution of aberrant methylation of this region in the regulation of EPHB2 expression.
In this study, we investigated the mechanisms of inactivation of EPHB2 in colorectal tumors and found that microsatellite unstable tumors have frequent mutations in the A9 repeat in exon 17 of EPHB2. Moreover, a CpG island in the proximal promoter region of this gene was hypermethylated in most of the colorectal tumors studied.

Materials and Methods

Cell lines and clinical samples. The cell lines used in this study were obtained and maintained as previously described (8). A total of 246 MSI colorectal carcinomas collected at medical institutions in Spain, Finland, Germany, and Japan were used in this study. The MSI status of these tumors was characterized as previously described (9–12). The 41 MSS colorectal tumors used for DNA hypermethylation analysis were collected at collaborating medical institutions in Spain and Finland. The series of 29 MSI adenomas from patients with hereditary nonpolyposis colorectal cancer used in this study has previously been described (9). Informed consent for genetic analysis of the tumor samples was obtained from each patient, according to the Human Investigations and Ethical Committee–approved research proposal in the corresponding institution.

EPHB2 mutation screening. The A9 repeat in exon 17 of the larger EPHB2 transcript (accession no., NM_017449) and flanking genomic DNA sequence were PCR-amplified in the 246 MSI tumor samples entered in this study (primer sequence and PCR conditions available upon request). Mutation screening in the amplified PCR fragments was done by direct automated sequencing (ABI 3100 capillary sequencer), fragment analysis (GeneScan Software, Applied Biosystems, Foster City, CA) and/or single-stranded conformational polymorphism, as previously described (9, 13, 14).

Methylation-specific PCR. DNA methylation status of an EPHB2 promoter-associated CpG island (from –537 to +836) was determined in colorectal tumor samples and cell lines included in the study by bisulfite conversion of unmethylated, but not methylated, cytosine to uracil as previously described (15). PCR reactions using primers specific for either the methylated or the modified unmethylated DNA (methylation-specific PCR) were carried out to determine the methylation profile of each sample. Primers were designed using MethPrimer 1.1 software. EPHB2 primers sequences for the methylated sequence were 5'-TTTGAATTTTTATATGTCGG- GGTAGAC-3' (sense) and 5'-CAATATTCCTCTCCCGAGCTCT-3' (antisense), and for the unmethylated sequence 5'-TTTTGAATTTTTATATGTCGG- GTAGAC-3' (sense) and 5'-CAATATTCCTCTCCCGAGCTCT-3' (antisense). PCR amplification was done using EcoStar DNA polymerase (Ecogen, Barcelona, Spain) under the following conditions: 95°C for 10 minutes, 35 cycles of 30 seconds at 95°C, 30 seconds at 68°C and 30 seconds at 72°C, and 4 minutes of final extension at 72°C. In vitro methylated DNA (CpG Genome Universal Methylated DNA; Chemicon International, Temecula, CA) was used as a positive control for methylated alleles, whereas DNA from normal lymphocytes and normal colon tissues were used as negative controls. Each PCR product was directly loaded onto 2% agarose gels, stained with ethidium bromide, and visualized under UV illumination.

Western blotting. SW620 cultures were treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine for 72 hours (0, 2, 5, or 10 µmol/L). Twenty micrograms of total protein (radioimmunoprecipitation assay buffer lysates) were fractionated in 8% SDS-polyacrylamide gels. Proteins were transferred to a polyvinylidene difluoride membrane (Amersham, Piscataway, NJ), blocked with 10% nonfat milk for 1 hour and then probed overnight at 4°C with a 1:100 dilution of anti-EPHB2 primary antibody (Stratagene, La Jolla, CA). Membranes were washed thrice with washing buffer (PBS with 0.1% Tween 20) and then probed with a peroxidase-conjugated secondary antibody for 1 hour (1:2,000; Boehringer Mannheim, Indianapolis, IN). After washing thrice with washing buffer, the signal was detected using enhanced chemiluminescence plus (Amersham) and a Storm PhosphorImager (Molecular Dynamics, Sunnyvale, CA). The membranes were then stripped and reprobed with an anti-β-actin antibody (clone AC74, 1:1,000; Sigma, St. Louis, MO). The signal from the β-actin probe was used as a loading control.

Results and Discussion

Frequent EPHB2 mutations in microsatellite instability tumors. The longer EPHB2 transcript contains an A9 track in exon 17 that could be a target for frameshift mutations in colorectal tumors with MSI. To investigate the possible mechanisms of EPHB2 inactivation in MSI tumors, we screened for mutations in the genomic region corresponding to exon 17 in a panel of 24 MSI colorectal cancer cell lines. Nine of these lines (37.5%) had a 1 bp deletion in the A9 repeat in exon 17. To further investigate the incidence of mutations in this repeat, we used a series of 246 primary MSI colorectal tumors. Frameshift
mutations were found in 41% of these tumors (101 of 246; Supplementary Table S1; Fig. 1). We analyzed the same region of EPHB2 in DNA samples obtained from matched normal tissue from all the mutation-positive patients. No changes were found in this A9 repeat, excluding the possibility of polymorphisms in this region as well as germ line mutations in these patients. No associations were found between mutations in EPHB2 and other clinicopathologic variables in MSI tumors (tumor stage, grade, patient sex, age, and 5-year survival; Supplementary Table S2).

Ninety-three percent of the mutations found in these MSI carcinomas (94 of 101) were deletions of one A in the A9 track (Fig. 1; Table 1). Two of the remaining cases had 2 bp deletions in this A9 repeat and three cases showed two mutated alleles (1 and 2 bp deletions). The remaining two cases had deletions in a T6 track 61 bp downstream of the A9 repeat in EPHB2. All the mutations found in EPHB2 change the translational reading frame, and result in changes in the amino acid sequence of the last 35 residues and the addition of a 26-amino acid tail, or the premature truncation of the protein (Table 1). In all cases, two serine residues (S1048 and S1052) that are predicted to be phosphorylated in the wild-type protein (16), and that could regulate the activity of this kinase, are lost in the mutant EPHB2.

To investigate whether EPHB2 mutations are an early event in the development of MSI colorectal tumors, we used a set of 29 MSI adenomas (9). We found that 20.7% of these adenomas (6 of 29) had a mutation in the A9 repeat of EPHB2 (Supplementary Table S1). The mutation frequency in this set of MSI adenomas (20.7%) was significantly lower than in MSI carcinomas (41%, 101 of 246; \( \chi^2 \) test; \( P = 0.03 \)). This observation is in good agreement with earlier reports showing that EPHB2 expression was reduced or lost in colorectal carcinomas, but not in adenomas (5), and further suggests that EPHB2 inactivation may be important for the transition from adenoma to carcinoma.

**Frequent hypermethylation of the EPHB2 promoter in colorectal tumors.** Cytosine hypermethylation in CpG dinucleotides in the regulatory region of tumor suppressor genes has been linked to reduced gene expression (7). Bisulfite treatment of genomic DNA allows precise analysis of methylation in a certain region by converting all nonmethylated cytosines into uracil, whereas methylated cytosines remain unchanged. PCR primers specific for the methylated or unmethylated sequence can then be used to investigate promoter hypermethylation (15).

The proximal promoter of EPHB2 contains a CpG island spanning 1,400 bp around the transcription start site, that could be hypermethylated and thus regulate the expression of this gene. We used a series of 60 MSI and 41 MSS colorectal tumors to investigate whether hypermethylation of the EPHB2 promoter could be a mechanism of gene inactivation in colorectal tumors. Of the 101 tumors investigated, 54 (53.4%) showed signs of EPHB2 promoter hypermethylation (Fig. 2A; Supplementary Table S1). There was no difference in the proportion of MSS and MSI tumors showing EPHB2 promoter methylation (51.2% and 55%, respectively; \( \chi^2 \) test; \( P = 0.7 \)) and no associations were found with other clinicopathologic features (patient age, sex, 5-year overall survival, tumor stage, grade and mutations in the A9 repeat in EPHB2 exon 17; Supplementary Table S3).

Using a panel of MSS colorectal cancer cell lines, we found evidence of promoter methylation in 5 out the 20 lines tested (25% data not shown). To investigate whether hypermethylation of CpG islands in the EPHB2 promoter is functionally relevant in reducing the expression levels of EPHB2, a cell line showing EPHB2 promoter methylation (SW620) was exposed to increasing concentrations of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine for 72 hours. This treatment resulted in a substantial up-regulation of EPHB2 protein levels in SW620 cells (Fig. 2B), demonstrating that aberrant methylation of the EPHB2 promoter can regulate EPHB2 expression.

Losses of large chromosomal regions are common in MSS tumors and deletions targeting important tumor suppressor genes confer a growth advantage to the cells and are clonally selected. EPHB2 is located in the short arm of chromosome 1 (1p36), one of the most commonly deleted areas in colorectal tumors (17–19). The frequent inactivation of EPHB2 by mutation and promoter hypermethylation described in this study is in good agreement with the high frequency of genomic losses in this region, and given the recently shown function of EPHB2 as a tumor suppressor gene in colorectal cancer (5), this gene could be an important target for at least some of these deletions.

In conclusion, in this study, we describe for the first time the mechanisms of EPHB2 inactivation in colorectal tumors. We found frequent mutations in repetitive sequences in exon 17 in MSI adenomas and carcinomas (21% and 41%, respectively) and hypermethylation of the EPHB2 promoter in the majority of the tumors of the colon and rectum (53%).

**Acknowledgments**

Received 7/22/2005; revised 9/7/2005; accepted 9/28/2005.

**Grant support:** Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by a Grant-in-Aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor, and Welfare of Japan (K. Izai, H. Yamamoto); the Deutsche Krebshilfe (S.M. Woerner, L. Konrad, J.F. Gebert); National Cancer Institute grant CA100823 (J.M. Mariadason), The Finnish Cancer Society, and the Academy of Finland.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Figure 2. *EPHB2* promoter hypermethylation in colorectal tumors. Primers specific for the bisulfite-transformed methylated or unmethylated sequence were used to PCR-amplify DNA samples from a series of 101 colorectal tumors (U, unmethylated; M, methylated). A, representative cases of tumors with and without EPHB2 hypermethylation. Arrows, tumors with EPHB2 promoter hypermethylation. B, as shown by Western blotting, treatment of SW620 cells with the indicated concentration of 5-aza-2'-deoxycytidine for 72 hours restored EPHB2 protein expression.
References

Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors

Hafid Alazzouzi, Veronica Davalos, Antti Kokko, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/22/10170

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2005/11/14/65.22.10170.DC1

Cited articles
This article cites 19 articles, 7 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/22/10170.full#ref-list-1

Citing articles
This article has been cited by 21 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/65/22/10170.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.